You are here

Our science / Clinical Trials / Find a Trial / NCT00150449

Determine Long-Term Safety and Tolerability of Pregabalin in Patients With Anxiety Disorders.

Back to Search Print Save as PDF Bookmark Trial

NCT00150449

Last updated on May 11, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
A-1040 Wien, , Austria
See other locations
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Anxiety Neuroses
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Must have completed the double-blind portion of the preceding trial

- Completed any protocol specified withdrawal phase and follow-up visits.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patient cannot participate if they experienced a serious adverse event or a
nonserious, but medically significant adverse event during the preceding efficacy
study that was judged to be related to the study medication.

NCT00150449
Pfizer
Completed
Determine Long-Term Safety and Tolerability of Pregabalin in Patients With Anxiety Disorders.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Dental Anxiety
Trial of Pregabalin, Alprazolam, and Placebo in Subjects With Anxiety Prior to Dental Procedure
NCT00245609
All Genders
18+
Years
Multiple Sites
Anxiety
Comparison of Pregabalin Versus Venlafaxine XR and Placebo in the Treatment of Generalized Anxiety Disorder
NCT00151450
All Genders
18+
Years
Multiple Sites
Anxiety Disorders
Study Of Remission In Patients Treated For Generalized Anxiety Disorder
NCT01788553
All Genders
Generalized Anxiety Disorder
Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD).
NCT00413010
All Genders
18+
Years
Multiple Sites
Determine Long-Term Safety and Tolerability of Pregabalin in Patients With Anxiety Disorders.
A 1-Year Open-Label Safety Extension Study of Pregabalin in Patients With Anxiety Disorders
Determine long-term safety and tolerability of pregabalin in patients with anxiety disorders.
Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Anxiety Neuroses
Drug: Pregabalin
Not Provided
Montgomery S, Emir B, Haswell H, Prieto R. Long-term treatment of anxiety disorders with pregabalin: a 1 year open-label study of safety and tolerability. Curr Med Res Opin. 2013 Oct;29(10):1223-30. doi: 10.1185/03007995.2013.820694. Epub 2013 Aug 19.


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
511
March 2006
Not Provided

Inclusion Criteria:

  • Must have completed the double-blind portion of the preceding trial
  • Completed any protocol specified withdrawal phase and follow-up visits.

Exclusion Criteria:

  • Patient cannot participate if they experienced a serious adverse event or a nonserious, but medically significant adverse event during the preceding efficacy study that was judged to be related to the study medication.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Austria,   Belgium,   Estonia,   France,   Germany,   Israel,   Italy,   Latvia,   Netherlands,   Poland,   South Africa,   Spain,   Ukraine,   United Kingdom
 
 
NCT00150449
1008-100
Not Provided
Not Provided
Not Provided
Not Provided
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
July 2006

ICMJE     Data element required by the

International Committee of Medical Journal Editors and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now